Bone Biologics Corp Financials

BBLG

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Weak

3/9

Bone Biologics Corp passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.00x

For every $1 of reported earnings, Bone Biologics Corp generates $1.00 in operating cash flow (-$4.1M OCF vs -$4.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows Bone Biologics Corp (BBLG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 20 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$4.1M

YoY+54.0%

Bone Biologics Corp reported -$4.1M in net income in fiscal year 2024. This represents an increase of 54.0% from the prior year.

EPS (Diluted)

$-4.83

YoY+85.8%

Bone Biologics Corp earned $-4.83 per diluted share (EPS) in fiscal year 2024. This represents an increase of 85.8% from the prior year.

Cash & Debt

$3.3M

YoY+9.9%

5Y CAGR+167.8%

10Y CAGR+2.3%

Bone Biologics Corp held $3.3M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

492,417

YoY-7.8%

Bone Biologics Corp had 492,417 shares outstanding in fiscal year 2024. This represents a decrease of 7.8% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$2.1M

YoY-69.2%

5Y CAGR+14.2%

10Y CAGR+13.1%

Bone Biologics Corp invested $2.1M in research and development in fiscal year 2024. This represents a decrease of 69.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

BBLG Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	$1.1B0.0%	$1.1B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.1M-69.2%	$6.9M+337.4%	$1.6M+1824.9%	$82K-75.9%	$341K-68.9%	$1.1M
SG&A Expenses	$2.1M-17.1%	$2.5M+20.8%	$2.1M+104.3%	$1.0M+110.8%	$484K-64.2%	$1.4M
Operating Income	-$4.2M+55.3%	-$9.4M-157.2%	-$3.7M-232.3%	-$1.1M-33.7%	-$825K+66.3%	-$2.4M
Interest Expense	N/A	$2K	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	$2K0.0%	$2K-0.2%	$2K
Net Income	-$4.1M+54.0%	-$8.9M-502.8%	-$1.5M+7.8%	-$1.6M+11.7%	-$1.8M+46.7%	-$3.4M
EPS (Diluted)	$-4.83+85.8%	$-34.01	$-31.15	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$188K-56.3%	$430K	N/A	$1.6M	N/A	$769K	N/A	$2K
SG&A Expenses	$527K+1.2%	$521K	N/A	$506K	N/A	$450K	N/A	$230K
Operating Income	-$715K+24.8%	-$951K	N/A	-$2.1M	N/A	-$1.2M	N/A	-$230K
Interest Expense	N/A	$255	N/A	$536	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$33K	N/A	N/A
Net Income	-$667K+29.1%	-$941K	N/A	-$1.9M	N/A	-$1.2M	N/A	-$509K
EPS (Diluted)	$-0.37	$-14.21	N/A	$-4.90	N/A	$-3.53	N/A	N/A

BBLG Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$3.9M+3.3%	$3.7M-56.0%	$8.5M+27.3%	$6.7M	$0-100.0%	$31K
Current Assets	$3.9M+3.3%	$3.7M-56.0%	$8.5M	N/A	N/A	$31K
Cash & Equivalents	$3.3M+9.9%	$3.0M-59.9%	$7.5M+12.9%	$6.7M+274380.5%	$2K-89.9%	$24K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$378K-54.6%	$831K-67.4%	$2.5M+2450.2%	$100K-99.3%	$13.7M+15.1%	$11.9M
Current Liabilities	$378K-54.6%	$831K-67.4%	$2.5M+2450.2%	$100K-99.3%	$13.7M+2267.1%	$578K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.5M+19.9%	$2.9M-51.1%	$5.9M-9.6%	$6.6M+148.0%	-$13.7M-15.4%	-$11.9M
Retained Earnings	-$85.0M-5.1%	-$80.9M-12.4%	-$72.0M-2.1%	-$70.5M-2.3%	-$68.9M-2.7%	-$67.0M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Total Assets	$6.4M+64.5%	$3.9M+3.3%	$3.7M-24.9%	$5.0M-41.4%	$8.5M+63.3%	$5.2M-22.1%	$6.7M+12640.9%	$52K
Current Assets	$6.4M+64.5%	$3.9M+3.3%	$3.7M	N/A	$8.5M	N/A	N/A	N/A
Cash & Equivalents	$6.0M+81.9%	$3.3M+9.9%	$3.0M-32.0%	$4.5M-40.9%	$7.5M+49.0%	$5.1M-24.2%	$6.7M+197747.2%	$3K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$334K-11.5%	$378K-54.6%	$831K-29.7%	$1.2M-53.6%	$2.5M+218.7%	$799K+700.2%	$100K-99.3%	$15.2M
Current Liabilities	$334K-11.5%	$378K-54.6%	$831K-29.7%	$1.2M-53.6%	$2.5M	N/A	$100K	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.0M+72.7%	$3.5M+19.9%	$2.9M-23.4%	$3.8M-36.2%	$5.9M+35.1%	$4.4M-33.1%	$6.6M+143.5%	-$15.1M
Retained Earnings	-$87.4M-2.9%	-$85.0M-5.1%	-$80.9M-2.0%	-$79.4M-10.3%	-$72.0M+1.2%	-$72.9M-3.4%	-$70.5M-0.3%	-$70.3M

BBLG Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$4.1M+56.8%	-$9.6M-167.9%	-$3.6M-190.3%	-$1.2M-187.8%	-$427K+86.9%	-$3.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$4.4M-12.3%	$5.0M+13.9%	$4.4M-44.0%	$7.9M+1862.3%	$403K-82.6%	$2.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Operating Cash Flow	-$591K+56.3%	-$1.4M+32.9%	-$2.0M+21.0%	-$2.6M-31.0%	-$2.0M-393.5%	-$395K-111.5%	-$187K+32.7%	-$278K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$0-100.0%	$1.1M+87.9%	$592K	$0	N/A	N/A	$6.9M+2378.7%	$277K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BBLG Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	-0.1%+0.1pp	-0.2%
Net Margin	N/A	N/A	N/A	N/A	-0.2%+0.2pp	-0.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-106.5%+132.9pp	-239.4%-221.9pp	-17.5%+6.6pp	-24.1%	N/A	-11109.8%
Current Ratio	10.22+5.7	4.50+1.2	3.33	N/A	N/A	0.05
Debt-to-Equity	0.11-0.2	0.29-0.1	0.43+0.4	0.02+1.0	-1.000.0	-1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-10.5%+12.6pp	-23.1%	N/A	-38.6%	N/A	-23.4%	N/A	-972.1%
Current Ratio	19.00+8.8	10.22+5.7	4.50	N/A	3.33	N/A	N/A	N/A
Debt-to-Equity	0.06-0.1	0.11-0.2	0.29-0.0	0.31-0.1	0.43+0.2	0.18+0.2	0.02+1.0	-1.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Nuwellis Inc NUWE

$1.8M

Catheter Precision VTAK

$2.5M

Venus Concept Inc VERO

$2.1M

Nanovibronix Inc NAOV

$4.4M

Tivic Health Systems Inc TIVC

$2.1M

Frequently Asked Questions

Is Bone Biologics Corp profitable?

No, Bone Biologics Corp (BBLG) reported a net income of -$4.1M in fiscal year 2024.

What is Bone Biologics Corp's earnings per share (EPS)?

Bone Biologics Corp (BBLG) reported diluted earnings per share of $-4.83 for fiscal year 2024. This represents a 85.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Bone Biologics Corp's operating cash flow?

Bone Biologics Corp (BBLG) generated -$4.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Bone Biologics Corp's total assets?

Bone Biologics Corp (BBLG) had $3.9M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Bone Biologics Corp spend on research and development?

Bone Biologics Corp (BBLG) invested $2.1M in research and development during fiscal year 2024.

How many shares does Bone Biologics Corp have outstanding?

Bone Biologics Corp (BBLG) had 492,417 shares outstanding as of fiscal year 2024.

What is Bone Biologics Corp's current ratio?

Bone Biologics Corp (BBLG) had a current ratio of 10.22 as of fiscal year 2024, which is generally considered healthy.

What is Bone Biologics Corp's debt-to-equity ratio?

Bone Biologics Corp (BBLG) had a debt-to-equity ratio of 0.11 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bone Biologics Corp's return on assets (ROA)?

Bone Biologics Corp (BBLG) had a return on assets of -106.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Bone Biologics Corp's cash runway?

Based on fiscal year 2024 data, Bone Biologics Corp (BBLG) had $3.3M in cash against an annual operating cash burn of $4.1M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bone Biologics Corp's Piotroski F-Score?

Bone Biologics Corp (BBLG) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bone Biologics Corp's earnings high quality?

Bone Biologics Corp (BBLG) has an earnings quality ratio of 1.00x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.